Overview

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Status:
Unknown status

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Shenzhen SiBiono GeneTech Co.,Ltd

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel